Anzeige
Mehr »
Login
Sonntag, 26.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Der SILBER-STURM kommt - wie diese unterbewertete Firma die Investmentwelt aufmischt und Milliardenwerte hebt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 904533 | ISIN: US74834L1008 | Ticker-Symbol: QDI
Tradegate
23.05.24
15:37 Uhr
129,75 Euro
-0,50
-0,38 %
Branche
Gesundheitswesen
Aktienmarkt
S&P 500
1-Jahres-Chart
QUEST DIAGNOSTICS INC Chart 1 Jahr
5-Tage-Chart
QUEST DIAGNOSTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
128,90131,0019:04
129,75130,7024.05.
ACCESSWIRE
331 Leser
Artikel bewerten:
(2)

Quest Diagnostics: On Rare Disease Day, Q4HE Collaboration Highlights Purpose in Action

NORTHAMPTON, MA / ACCESSWIRE / February 29, 2024 / Quest Diagnostics

No-cost laboratory testing: Fourth-year dental student, Tyesha Younger MS, and Mark Mintline DDS diagnose a case of pemphigus vulgaris as part of the Biopsies Save Lives program. Photo credit: WesternU

In honor of Rare Disease Day on February 29, we're highlighting a program dedicated to diagnosing and treating patients in underserved communities in Southern California affected by the rare autoimmune diseases pemphigus and pemphigoid, which can be life-threatening if left untreated.

Last year, we announced that Quest Diagnostics teamed up with Western University of Health Sciences (WesternU) to offer no-cost diagnostic testing services to support Biopsies Save Lives as part of the Quest for Health Equity (Q4HE) initiative. The program offers no-cost testing to patients who are low-income, uninsured, and/or underinsured and who also have rare erosive and blistering diseases, and enables faster diagnosis and treatment of these conditions.

Since the collaboration between Q4HE and WesternU started, the Biopsies Save Lives program has helped lead to the potentially life-saving diagnosis of 3 patients affected by these rare diseases.

"We are very thankful to Quest Diagnostics and their Quest for Health Equity initiative for supporting the Biopsies Save Lives program," said WesternU Health Oral Pathology Laboratory Director Mark Mintline, DDS. "Biopsies Save Lives breaks down financial barriers to laboratory testing and turns the scariest part of healthcare-waiting for results from a potentially life-changing test-into one that is most welcoming, supportive, and educational. The no-cost laboratory testing that Quest is providing has been critical for our patients, and the support has been a blessing for underserved communities with erosive and blistering diseases in Los Angeles County."

Through Biopsies Save Lives, patients better understand their blistering diseases, how to ask their providers questions, and are connected to expert dermatologists.

"This is a great, real-world example of how we are working together to create a healthier world, one life at a time, and highlights the positive impact our work has on patients," said Cynita Smith-Watson, Senior Manager, Regional Contracting for Q4HE.

Rare Disease Day is an observance held on the last day of February to raise awareness of rare diseases and improve access to treatment and medical representation for individuals with rare diseases and their families.

To learn more about the Biopsies Save Lives program, visit www.pemphigus.org/biopsies-save-lives/.

View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com.

Contact Info:
Spokesperson: Quest Diagnostics
Website: https://www.3blmedia.com/profiles/quest-diagnostics
Email: info@3blmedia.com

SOURCE: Quest Diagnostics



View the original press release on accesswire.com

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2024 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.